Trial Profile
A Prospective, Multi-national, Multi-center, Double-blind, Randomized, Active Controlled, Parallel-group, Seamless Phase II/III Clinical Study to Evaluate the Safety and Immunogenicity of 'LBVC (Sabin Poliomyelitis Vaccine (Inactivated))' Compared With 'Imovax® Polio (Poliomyelitis Vaccine (Inactivated))' in Healthy Infants
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 30 Dec 2020
Price :
$35
*
At a glance
- Drugs Poliovirus vaccine inactivated (Primary)
- Indications Poliomyelitis
- Focus Pharmacodynamics
- Sponsors LG Chem; LG Life Sciences
- 22 Dec 2020 Primary endpoint (Seroconversion rate(%)) has been met as per results published in the Journal of Infectious Diseases
- 22 Dec 2020 Results published in the Journal of Infectious Diseases
- 27 Aug 2019 Status changed from active, no longer recruiting to completed.